Live Well. Do Tell. Take Action


Ron Cohen, M.D., President, CEO and Founder Acorda Therapeutics

Take Action

“The trick is figuring out how best to use our shared understanding and make it of value.” - Ron Cohen, M.D., President, CEO and Founder Acorda Therapeutics

Learn More & Take Action

Download the "Live Well. Do Tell." Statement of Need to read more insights from the multidisciplinary Steering Committee as well as research conducted by Acorda and third parties.

Actions for the Community

Based on guidance from the Steering Committee, we recommend the following actions:

Tailor icon

resources at diagnosis and at various inflection points over time to address the individual needs of people with Parkinson’s.

Broaden icon

the Parkinson’s community’s current understanding of what OFF is and isn’t, particularly with regard to the non-motor aspects of OFF.

Educate icon

that fluctuations are an expected aspect of Parkinson’s that don’t necessarily indicate progression to encourage conversations about OFF in the doctor’s office.

Identify icon

opportunities for care partners to effectively share their observations of Parkinson’s symptoms with healthcare professionals (HCPs).

Enhance icon

the dialogue between HCPs and people with Parkinson's to capture the full impact of OFF and address sources of well-being and ill-being.

Motivate icon

improvements in HCP clinical practice habits via education by movement disorder experts and the establishment of a real-world, validated tool to measure OFF periods.

Bringing Voices Together

Hear from Ron Cohen, M.D., President, CEO and Founder of Acorda Therapeutics, Matthew Stern, M.D., Professor Emeritus of Neurology, Perelman School of Medicine, University of Pennsylvania, and Steve DeWitte, who has been living with Parkinson’s since 2005, about the importance of bringing together the circle of the care to improve conversations around Parkinson’s.

Join the Conversation

Click to sign up to register for future communications and stay informed on the latest news and developments.